Oncology Drug Development and Value-Based Medicine

The growing voice of stakeholders, from patients to payers, is changing the path of drug development. Nowhere is this trend more evident than in the oncology space. While evidence-based clinical medicine still stands as the prime driver, the additional driver that is emerging is overall treatment value. Value-based medicine is at the heart of a broadening debate on a host of topics, including the quality of cancer care, access to treatments and the differing stakeholder expectations of drug therapy.

Read the white paper.